Brief: Seelos Doses First Patient In Open Label Basket Study Of SLS-005 In ALS In Australia
18/07/2022 13:48
July 18 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS DOSES FIRST PATIENT IN AN OPEN LABEL
BASKET
STUDY OF SLS-005 IN AMYOTROPHIC LATERAL SCLEROSIS IN AUSTRALIA
AND PROVIDES AN ENROLLMENT UPDATE OF ITS STUDY ON THE HEALEY ALS
PLATFORM
* SEELOS THERAPEUTICS - SLS-005 STUDY ON HEALEY ALS PLATFORM
IS
EXPECTED TO COMPLETE ENROLLMENT THIS QUARTER; TOP-LINE DATA
READOUT EXPECTED MID-2023
Source text for Eikon: ID:nPnc93Kf8a
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio